LBP 1 (drug)

LBP-1 is a drug originally developed by Organon for the treatment of neuropathic pain, and subsequently further developed by Merck after they acquired Organon's patents following their merger with Schering-Plough. It acts as a potent and selective cannabinoid receptor agonist, with high potency at both the CB₁ and CB₂ receptors, but low penetration of the blood–brain barrier. This makes LBP-1 peripherally selective, and while it was effective in animal models of neuropathic pain and allodynia, it did not produce cannabinoid-appropriate responding suggestive of central effects, at any dose tested.